The University of Chicago Header Logo

Connection

Mark J. Ratain to Genotype

Back to Details
This is a "connection" page, showing publications Mark J. Ratain has written about Genotype.
Mark J. Ratain
Connection Strength
1.982
Genotype
  1. Influence of N-acetyltransferase 2 gene polymorphisms on the in vitro metabolism of the epidermal growth factor receptor inhibitor rociletinib. Br J Clin Pharmacol. 2021 11; 87(11):4313-4322.
    View in: PubMed
    Score: 0.137
  2. A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance). Clin Pharmacol Ther. 2019 03; 105(3):738-745.
    View in: PubMed
    Score: 0.116
  3. Disease-drug database for pharmacogenomic-based prescribing. Clin Pharmacol Ther. 2016 08; 100(2):179-90.
    View in: PubMed
    Score: 0.098
  4. Meaningful use of pharmacogenetics. Clin Pharmacol Ther. 2014 Dec; 96(6):650-2.
    View in: PubMed
    Score: 0.088
  5. Incorporating biomarkers into drug labeling. Clin Adv Hematol Oncol. 2014 Aug; 12(8):525-8.
    View in: PubMed
    Score: 0.086
  6. Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer. J Clin Oncol. 2014 Aug 01; 32(22):2328-34.
    View in: PubMed
    Score: 0.085
  7. Adoption of a clinical pharmacogenomics implementation program during outpatient care--initial results of the University of Chicago "1,200 Patients Project". Am J Med Genet C Semin Med Genet. 2014 Mar; 166C(1):68-75.
    View in: PubMed
    Score: 0.084
  8. Germline pharmacogenomics in oncology: decoding the patient for targeting therapy. Mol Oncol. 2012 Apr; 6(2):251-9.
    View in: PubMed
    Score: 0.072
  9. A pharmacogenetic study of vorinostat glucuronidation. Pharmacogenet Genomics. 2010 Oct; 20(10):638-41.
    View in: PubMed
    Score: 0.066
  10. Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin. 2009 Jan-Feb; 59(1):42-55.
    View in: PubMed
    Score: 0.058
  11. Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet? Pharmacotherapy. 2008 Jun; 28(6):755-68.
    View in: PubMed
    Score: 0.056
  12. Personalized medicine: building the GPS to take us there. Clin Pharmacol Ther. 2007 Mar; 81(3):321-2.
    View in: PubMed
    Score: 0.051
  13. Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping. Pharmacogenomics. 2006 Dec; 7(8):1211-21.
    View in: PubMed
    Score: 0.051
  14. TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy? Trends Pharmacol Sci. 2006 Aug; 27(8):432-7.
    View in: PubMed
    Score: 0.049
  15. "Irinogenetics" and UGT1A: from genotypes to haplotypes. Clin Pharmacol Ther. 2004 Jun; 75(6):495-500.
    View in: PubMed
    Score: 0.043
  16. Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. Clin Cancer Res. 2003 Mar; 9(3):1009-12.
    View in: PubMed
    Score: 0.039
  17. Correspondence re: Raida, M. et al., prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res. 2002 May; 8(5):1314; author reply 1315-6.
    View in: PubMed
    Score: 0.037
  18. Clinically actionable genotypes for anticancer prescribing among >1500 patients with pharmacogenomic testing. Cancer. 2022 Apr 15; 128(8):1649-1657.
    View in: PubMed
    Score: 0.036
  19. Validation of a Large Custom-Designed Pharmacogenomics Panel on an Array Genotyping Platform. J Appl Lab Med. 2021 11 01; 6(6):1505-1516.
    View in: PubMed
    Score: 0.036
  20. Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer. J Clin Oncol. 2001 Apr 01; 19(7):2084-90.
    View in: PubMed
    Score: 0.034
  21. Gazing into a crystal ball-cancer therapy in the post-genomic era. Nat Med. 2001 Mar; 7(3):283-5.
    View in: PubMed
    Score: 0.034
  22. Pharmacogenetics: a tool for individualizing antineoplastic therapy. Clin Pharmacokinet. 2000 Nov; 39(5):315-25.
    View in: PubMed
    Score: 0.033
  23. Pharmacogenomic-Based Decision Support to Predict Adherence to Medications. Clin Pharmacol Ther. 2020 08; 108(2):368-376.
    View in: PubMed
    Score: 0.032
  24. Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015. Breast Cancer Res Treat. 2020 Jun; 181(3):623-633.
    View in: PubMed
    Score: 0.032
  25. A New Liver Expression Quantitative Trait Locus Map From 1,183 Individuals Provides Evidence for Novel Expression Quantitative Trait Loci of Drug Response, Metabolic, and Sex-Biased Phenotypes. Clin Pharmacol Ther. 2020 06; 107(6):1383-1393.
    View in: PubMed
    Score: 0.031
  26. Analysis of comprehensive pharmacogenomic profiling to impact in-hospital prescribing. Pharmacogenet Genomics. 2019 02; 29(2):23-30.
    View in: PubMed
    Score: 0.029
  27. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. Clin Pharmacol Ther. 2018 05; 103(5):770-777.
    View in: PubMed
    Score: 0.027
  28. ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia. Pharmacogenomics J. 2018 01; 18(1):35-42.
    View in: PubMed
    Score: 0.025
  29. Providing Balance in ASCO Clinical Practice Guidelines: CYP2D6 Genotyping and Tamoxifen Efficacy. J Clin Oncol. 2016 11 10; 34(32):3944-3945.
    View in: PubMed
    Score: 0.025
  30. Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy. Clin Cancer Res. 2016 Oct 01; 22(19):4890-4900.
    View in: PubMed
    Score: 0.024
  31. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing. Clin Pharmacol Ther. 2016 Apr; 99(4):363-9.
    View in: PubMed
    Score: 0.023
  32. Evidence for Clinical Implementation of Pharmacogenomics in Cardiac Drugs. Mayo Clin Proc. 2015 Jun; 90(6):716-29.
    View in: PubMed
    Score: 0.023
  33. Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study. Pharmacogenomics J. 2016 Feb; 16(1):54-9.
    View in: PubMed
    Score: 0.023
  34. Glucuronidation of OTS167 in Humans Is Catalyzed by UDP-Glucuronosyltransferases UGT1A1, UGT1A3, UGT1A8, and UGT1A10. Drug Metab Dispos. 2015 Jul; 43(7):928-35.
    View in: PubMed
    Score: 0.023
  35. Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies. J Natl Cancer Inst. 2014 Dec 08; 107(2).
    View in: PubMed
    Score: 0.022
  36. Establishment of CYP2D6 reference samples by multiple validated genotyping platforms. Pharmacogenomics J. 2014 Dec; 14(6):564-72.
    View in: PubMed
    Score: 0.021
  37. A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469. Pharmacogenet Genomics. 2014 Feb; 24(2):129-32.
    View in: PubMed
    Score: 0.021
  38. Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients. PLoS One. 2013; 8(1):e54522.
    View in: PubMed
    Score: 0.019
  39. A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res. 2012 Sep 15; 18(18):5099-109.
    View in: PubMed
    Score: 0.019
  40. Identification, replication, and functional fine-mapping of expression quantitative trait loci in primary human liver tissue. PLoS Genet. 2011 May; 7(5):e1002078.
    View in: PubMed
    Score: 0.017
  41. The UGT1A1*28 polymorphism correlates with erlotinib's effect on SN-38 glucuronidation. Eur J Cancer. 2010 Jul; 46(11):2097-103.
    View in: PubMed
    Score: 0.016
  42. Vascular endothelial growth factor pathway. Pharmacogenet Genomics. 2010 May; 20(5):346-9.
    View in: PubMed
    Score: 0.016
  43. The Werner's syndrome 4330T>C (Cys1367Arg) gene variant does not affect the in vitro cytotoxicity of topoisomerase inhibitors and platinum compounds. Cancer Chemother Pharmacol. 2009 Apr; 63(5):881-7.
    View in: PubMed
    Score: 0.014
  44. Lack of association between common polymorphisms in UGT1A9 and gene expression and activity. Drug Metab Dispos. 2007 Dec; 35(12):2149-53.
    View in: PubMed
    Score: 0.013
  45. UGT1A1*28 genotype affects the in-vitro glucuronidation of thyroxine in human livers. Pharmacogenet Genomics. 2007 Aug; 17(8):619-27.
    View in: PubMed
    Score: 0.013
  46. Hepatocyte nuclear factor-1 alpha is associated with UGT1A1, UGT1A9 and UGT2B7 mRNA expression in human liver. Pharmacogenomics J. 2008 Apr; 8(2):152-61.
    View in: PubMed
    Score: 0.013
  47. Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests. Clin Pharmacol Ther. 2005 Dec; 78(6):559-81.
    View in: PubMed
    Score: 0.012
  48. Global gene expression as a function of germline genetic variation. Hum Mol Genet. 2005 Jun 15; 14(12):1621-9.
    View in: PubMed
    Score: 0.011
  49. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 2004 Apr 15; 22(8):1382-8.
    View in: PubMed
    Score: 0.010
  50. A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine. Clin Pharmacol Ther. 2003 Jun; 73(6):566-74.
    View in: PubMed
    Score: 0.010
  51. Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics. 2002 Dec; 12(9):725-33.
    View in: PubMed
    Score: 0.010
  52. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2002; 2(1):43-7.
    View in: PubMed
    Score: 0.009
  53. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther. 1999 May; 65(5):576-82.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.